AMRX
Amneal Pharmaceuticals Inc.
$12.79
+$0.37(+2.98%)
46
Overall
40
Value
36
Tech
63
Quality
Market Cap
$3.60B
Volume
2.11M
52W Range
$7.07 - $15.42
Target Price
$17.20
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | $1.0B | $1.7B | $1.8B | $2.0B | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B | ||
| Total Revenue | $1.0B | $1.7B | $1.6B | $2.0B | $2.1B | $2.2B | $2.4B | $2.8B | $3.0B | ||
| COST OF GOODS SOLD | |||||||||||
| Cost of Revenue | $-507.5M | $-938.8M | $1.1B | $1.4B | $1.3B | $1.4B | $1.6B | $1.8B | $1.9B | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | $526.2M | $716.4M | $479.2M | $628.4M | $769.0M | $784.7M | $820.6M | $1.0B | $1.1B | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $289.9M | $660.1M | $475.5M | $508.3M | $561.6M | $595.8M | $592.5M | $666.2M | $707.8M | ||
| Research & Development | $171.4M | $194.2M | $188.0M | $179.9M | $201.8M | $195.7M | $163.9M | $190.7M | $186.2M | ||
| Research Expense | $171.4M | $194.2M | $188.0M | $179.9M | $201.8M | $195.7M | $163.9M | $190.7M | $186.2M | ||
| Selling, General & Administrative | $109.0M | $227.8M | $289.6M | $326.7M | $365.5M | $399.7M | $429.7M | $476.4M | $526.8M | ||
| Selling & Marketing Expenses | $109.0M | $227.8M | -- | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-17.0M | $-18.0M | $289.6M | $326.7M | $365.5M | $399.7M | $429.7M | $476.4M | $526.8M | ||
| Salaries & Wages | $9.4M | $221.8M | $-16.4M | $-9.0M | $-13.4M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-42.0M | $-64.4M | $63.3M | $60.4M | $60.7M | $68.1M | $66.2M | $62.6M | -- | ||
| Depreciation & Amortization | $-42.0M | $-64.4M | $63.3M | $60.4M | $60.7M | -- | -- | -- | -- | ||
| Amortization | $-8.6M | $-78.8M | $1.4B | $1.3B | $1.2B | $1.1B | $895.4M | $737.0M | -- | ||
| Other Operating Expenses | -- | $16.3M | $14.2M | $10.7M | $7.7M | $398.0K | $-1.1M | $-930.0K | $-5.2M | ||
| OPERATING INCOME | |||||||||||
| Operating income | $236.3M | $56.3M | $-248.7M | $91.2M | $152.7M | $-94.9M | $204.4M | $249.3M | $394.1M | ||
| EBITDA | $220.8M | $-47.3M | $34.5M | $345.6M | $401.1M | $159.0M | $182.0M | $232.7M | $402.7M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | $-1.4M | -- | $4.6M | $146.0M | $136.3M | $158.4M | $210.6M | $258.6M | $241.1M | ||
| Intinc | $-71.1M | $-141.9M | $-168.2M | $-146.0M | $-136.3M | $-158.4M | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-69.6M | $-141.9M | $-168.2M | $-146.0M | $-136.3M | $158.7M | $-210.6M | $-258.6M | $-241.1M | ||
| Gain on Sale of Securities | $-29.2M | $-3.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $31.8M | $21.8M | $-194.3M | $-2.6M | $-15.1M | $-278.4M | $18.1M | $-11.8M | $14.9M | ||
| Other Special Charges | $-2.6M | $-18.8M | $194.3M | $2.6M | $15.3M | $17.5M | $-32.6M | $11.8M | $-14.9M | ||
| SPECIAL ITEMS | |||||||||||
| Restructring And Mn A Income | -- | $56.4M | $34.3M | $2.4M | $1.9M | $1.4M | $1.7M | $2.4M | $4.2M | ||
| Special Income Charges | $8.8M | $-76.0M | $-93.4M | $-10.9M | $-27.6M | $-284.3M | $-34.4M | $-99.0M | $-3.8M | ||
| Impairment of Capital Assets | $-3.9M | $39.3M | $46.6M | $2.7M | $710.0K | $13.0M | $30.8M | -- | -- | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $169.9M | $-201.0M | $-215.6M | $110.2M | $167.7M | $-89.8M | $170.4M | $203.6M | $380.3M | ||
| Pre-Tax Income | $171.3M | $-202.7M | $-220.2M | $-35.8M | $31.4M | $-248.1M | $-40.3M | $-55.0M | $139.2M | ||
| INCOME TAX | |||||||||||
| Tax Provision | $2.0M | $-1.4M | $383.3M | $-104.4M | $11.2M | $6.7M | $8.5M | $18.9M | $11.3M | ||
| NET INCOME | |||||||||||
| Net Income | $169.1M | $-21.8M | $-361.9M | $91.1M | $10.6M | $-130.0M | $-84.0M | $-116.9M | $72.1M | ||
| Net Income (Continuing Operations) | $169.1M | $-21.8M | $-361.9M | $91.1M | $10.6M | $-254.8M | $-48.7M | $-73.9M | $127.9M | ||
| Net Income (Discontinued Operations) | $169.1M | $-21.8M | $-361.9M | $91.1M | $10.6M | $-130.0M | $-84.0M | $-116.9M | $72.1M | ||
| Net Income (Common Stockholders) | $1.4M | $-23.0M | $-361.9M | $91.1M | $10.6M | $-130.0M | $-84.0M | $-116.9M | $72.1M | ||
| TOTALS | |||||||||||
| Total Expenses | $-217.6M | $-278.7M | $1.6B | $1.8B | $1.9B | $2.0B | $2.2B | $2.4B | $2.6B | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | -- | $127.3M | $132.1M | $147.4M | $148.9M | $150.9M | $176.1M | $309.0M | $313.4M | ||
| Average Shares Outstanding (Diluted) | -- | $1.1B | -- | $148.9M | $151.8M | $150.9M | $176.1M | $309.0M | $324.8M | ||
| Shares Outstanding | $1.0K | $298.7M | $299.2M | $299.8M | $301.5M | $303.6M | $307.0M | $310.0M | $314.6M | ||
| Basic EPS | -- | $-0.07 | $-2.74 | $0.62 | $0.07 | $-0.86 | $-0.48 | $-0.38 | $0.23 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-2.74 | $0.62 | $0.07 | $-0.86 | $-0.48 | $-0.38 | $0.23 | ||
| Diluted EPS | -- | $-0.16 | $-2.74 | $0.61 | $0.07 | $-0.86 | $-0.48 | $-0.38 | $0.22 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $0.61 | $0.07 | $-0.86 | $-0.48 | $-0.38 | $0.22 | ||
| OTHER METRICS | |||||||||||
| Accretion On Preferred Stock | $-375.3M | $1.2M | -- | -- | -- | $438.0K | -- | -- | -- | ||
| Accrued Preferred Stock Dividends | $167.6M | $-148.8M | -- | -- | -- | -- | -- | -- | -- | ||
| Acquisition Expense | -- | -- | $16.4M | $9.0M | $8.1M | -- | -- | -- | -- | ||
| Fees | -- | $-1.7M | -- | -- | -- | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | $7.3M | $123.0K | -- | -- | -- | -- | -- | ||
| Interest Expense Operating | -- | $1.7M | -- | -- | -- | -- | -- | -- | -- | ||
| Minority Interests | $-1.7M | $32.8M | $241.7M | $22.5M | $-9.5M | $124.8M | $-35.3M | $-43.0M | $-55.9M | ||
| Net Income Discontinuous Operations | -- | -- | $7.3M | $123.0K | -- | -- | -- | -- | -- | ||
| Net Income From Other Gains Losses | -- | $148.8M | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | $-8.8M | $-19.7M | $12.4M | $5.9M | $25.0M | $269.9M | $1.8M | $96.7M | $-390.0K | ||
| Other Gand A | $-17.0M | $-18.0M | $289.6M | $326.7M | $365.5M | $399.7M | $429.7M | $476.4M | $526.8M | ||
| Other Impairment Of Capital Assets | -- | -- | $2.0M | $1.0M | -- | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $167.6M | $1.2M | -- | -- | -- | $438.0K | -- | -- | -- | ||
| Rent And Landing Fees | $-17.0M | $-18.0M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $109.0M | $227.8M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | $56.4M | $34.3M | $2.4M | $1.9M | $1.4M | $1.7M | $2.4M | $4.2M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AMRX | $12.79 | +3.0% | 2.11M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Amneal Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW